Novo Nordisk has entered a partnership with Vivtex to develop next generation oral biologic medicines for obesity and diabetes. The company has approved a €432 million investment to expand its oral ...

Novo Nordisk is expanding its tabletting facility in Monksland, Athlone, Ireland with a 432 million euro ($372.5 million) ...

Both Novo and obesity market rival Eli Lilly have outlaid significant funds to ensure future demand for oral weight loss drugs is met.

Pharmaceutical company Novo Nordisk has announced a €430m expansion of its manufacturing operation in Athlone which will see it produce the tablet form of its weight loss drug Wegovy.

Novo Nordisk has said it will invest DKK 3.2 billion (€432 million) in a manufacturing plant in Ireland that will be used to ...

Novo Nordisk today announced an investment of 432 million euro ($510 million) in its facility in Monksland, Athlone, Ireland. This tabletting facility will provide significant additional manufacturing ...

Novo Nordisk has today announced an investment of €432 million in its facility in Monksland, Athlone. This tabletting ...

Novo Nordisk has announced an investment of €432 million in its facility in Athlone. The investment will facilitate an expansion in its manufacturing facility in Monksland. This tabletting facility ...

Bagsværd, Denmark, 2 March 2026 - Novo Nordisk today announced an investment of 432 million euro (approx. DKK 3.2 billion) in ...

Weight-loss drug pioneer Novo Nordisk will invest €432 million in upgrading its Athlone plant to produce the tablet form of its Wegovy therapy. The company said the Irish tabletting facility would ...

Pfizer Global Research and Development, and Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, U.K. Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 ...